Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8AIV

Mpro of SARS COV-2 in complex with the MG-100 inhibitor

This is a non-PDB format compatible entry.
Summary for 8AIV
Entry DOI10.2210/pdb8aiv/pdb
Descriptor3C-like proteinase nsp5, tert-butyl N-[1-[(2S)-3-cyclopropyl-1-[[(2S,3R)-4-(methylamino)-3-oxidanyl-4-oxidanylidene-1-[(3S)-2-oxidanylidenepyrrolidin-3-yl]butan-2-yl]amino]-1-oxidanylidene-propan-2-yl]-2-oxidanylidene-pyridin-3-yl]carbamate, CHLORIDE ION, ... (4 entities in total)
Functional Keywordsinhibitor complex, sars-cov-2, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus
Total number of polymer chains2
Total formula weight68725.73
Authors
El Kilani, H.,Hilgenfeld, R. (deposition date: 2022-07-27, release date: 2023-08-16, Last modification date: 2025-01-29)
Primary citationAkula, R.K.,El Kilani, H.,Metzen, A.,Roske, J.,Zhang, K.,Gohl, M.,Arisetti, N.,Marsh, G.P.,Maple, H.J.,Cooper, M.S.,Karadogan, B.,Jochmans, D.,Neyts, J.,Rox, K.,Hilgenfeld, R.,Bronstrup, M.
Structure-Based Optimization of Pyridone alpha-Ketoamides as Inhibitors of the SARS-CoV-2 Main Protease.
J.Med.Chem., 2025
Cited by
PubMed Abstract: The main protease M is a clinically validated target to treat infections by the coronavirus SARS-CoV-2. Among the first reported M inhibitors was the peptidomimetic α-ketoamide , whose cocrystal structure with M paved the way for multiple lead-finding studies. We established structure-activity relationships for the series by modifying residues at the P1', P3, and P4 sites. Guided by cocrystal structures, we reduced the P1' substituent size to better fill the pocket and added a fluorine substituent to the pyridone ring, enabling a new hydrogen bond with Gln189 in P3. Among 22 novel analogues, and inhibited M with ICs of 110 nM and 40 nM, improving the potency of by up to 9.5-fold. Compound had pronounced antiviral activity with an EC of 1.6 μM and was stable in plasma and microsomes. The study illustrates the potential of structure-based design to systematically improve peptidomimetic α-ketoamides.
PubMed: 39817813
DOI: 10.1021/acs.jmedchem.4c02172
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

230744

PDB entries from 2025-01-29

PDB statisticsPDBj update infoContact PDBjnumon